

Canagliflozin (Type 2 Diabetes) - Analysis and Forecasts to 2020

Description: Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020" provides Canagliflozin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU% and Japan (seven major markets)
- Analysis and review of Canagliflozin
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Canagliflozin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for Canagliflozin in the US, EU5 and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Canagliflozin, Type 2 Diabetes, Diabetes, Sales Forecasts, Sodium Glucose Transporter-2 (SGLT2), Phase III, Phase 3, Pipeline, Competitors to Canagliflozin - Lantus, Onglyza, Januvia, Janumet and Victoza, Johnson & Johnson

Contents:

- 1
- 1
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Introduction
- 2.1 Diabetes
- 2.2 Epidemiology
- 2.2.1 Prevalence
- 2.2.2 Mortality
- 2.3 Etiology and Risk Factors
- 2.3.1 Obesity
- 2.3.2 Sedentary Lifestyle
- 2.3.3 Family History and Genetics
- 2.3.4 Ethnicity
- 2.3.5 Old Age

- 2.4 Economic Impact of Diabetes
- 2.5 GlobalData Report Guidance
- 3 Type 2 Diabetes: Market Characterization
 - 3.1 Type 2 Diabetes Market
 - 3.2 Type 2 Diabetes Market Forecasts
 - 3.3 Type 2 Diabetes Market: Drivers and Restraints
 - 3.3.1 Drivers
 - 3.3.2 Restraints
- 4 Classification of Diabetes
 - 4.1 Types of Diabetes
 - 4.1.1 Type 1 Diabetes
 - 4.1.2 Type 2 Diabetes
 - 4.1.3 Gestational Diabetes
 - 4.2 Diabetes Complications
 - 4.2.1 Cardiovascular Disease
 - 4.2.2 Nephropathy
 - 4.2.3 Neuropathy
 - 4.2.4 Amputation
 - 4.2.5 Retinopathy
- 5 Evolution of Anti-Diabetic Treatments
- 6 Medications
 - 6.1 Insulin
 - 6.2 Oral Medications
 - 6.2.1 Sulfonylureas (SUR)
 - 6.2.2 Biguanides (BGDs)
 - 6.2.3 Alpha-Glucosidase Inhibitors (AGI)
 - 6.2.4 Meglitinides
 - 6.2.5 Thiozolidinediones (TZDs)
 - 6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors
 - 6.2.7 Oral Combination Therapy
 - 6.3 Other Injectionable Medications
 - 6.3.1 Pramlintide
 - 6.3.2 Exenatide
 - 6.4 Market Share as per Classes in Type 2 Diabetes
- 7 Canagliflozin
 - 7.1 Introduction
 - 7.2 Mechanism of Action
 - 7.3 Clinical Studies
 - 7.3.1 A Phase II Trial Evaluating Canagliflozin Vs Januvia for the Treatment of NIDDM Patients
 - 7.3.2 A Phase III Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Canagliflozin Compared with Amaryl for the Treatment of Type 2 Diabetes
 - 7.3.3 A Phase III Clinical Trial Evaluating Canagliflozin as a Monotherapy in Type 2 Diabetes Non Insulin Diabetes Mellitus Patients
 - 7.4 Factors Affecting Sales of Canagliflozin
 - 7.4.1 Emergence of SGLT2 inhibitors
 - 7.4.2 No Weight Gain
 - 7.5 Drug Evaluation
 - 7.5.1 Drug Risk Benefit Score
 - 7.5.2 Intensity of Competition
 - 7.6 Sales Forecasts
 - 7.6.1 Dosing
 - 7.6.2 Market Penetration
 - 7.6.3 Annual Cost of Therapy
 - 7.6.4 Sales Projections of Canagliflozin
- 8 Diabetes Market: Appendix
 - 8.1 Market Definitions
 - 8.2 List of Abberiviations
 - 8.3 Research Methodology
 - 8.3.1 Coverage
 - 8.3.2 Secondary Research
 - 8.3.3 Forecasting
 - 8.3.4 Number of patients approved to take the drug
 - 8.3.5 Net Penetration of Drug

- 8.3.6 Net Annual Dosing
- 8.3.7 Annual Cost of Therapy
- 8.4 Drug Sales Estimates Model
- 8.5 Contact Us
- 8.6 Disclaimer
- 8.7 Sources

1.1 List of Tables

- Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
- Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
- Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures (\$bn), 2010
- Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales (\$m), 2010
- Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trails
- Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
- Table 7: Overweight-, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
- Table 8: Diabetes Drugs Evolution
- Table 9: Drug Risk Benefit Score (DRB), Canagliflozin
- Table 10: Canagliflozin, Type 2 Diabetes, Global, Sales Forecasts (\$m), 2013–2020
- Table 11: Canagliflozin, Type 2 Diabetes, The US, Sales Forecasts (\$m), 2013–2020
- Table 12: Canagliflozin, Type 2 Diabetes, The UK, Sales Forecasts (\$m), 2013–2020
- Table 13: Canagliflozin, Type 2 Diabetes, France, Sales Forecasts (\$m), 2013–2020
- Table 14: Canagliflozin, Type 2 Diabetes, Germany, Sales Forecasts (\$m), 2013–2020
- Table 15: Canagliflozin, Type 2 Diabetes, Italy, Sales Forecasts (\$m), 2013–2020
- Table 16: Canagliflozin, Type 2 Diabetes, Spain, Sales Forecasts (\$m), 2013–2020
- Table 17: Canagliflozin, Type 2 Diabetes, Japan, Sales Forecasts (\$m), 2016–2020

1.2 List of Figures

- Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010
- Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030
- Figure 3: Diabetes, World, Mortality, 2010
- Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
- Figure 5: Type 2 Diabetes, Global, Market Size Forecasts (\$bn), 2010–2020
- Figure 6: Mechanism of Action of Sulfonylureas
- Figure 7: Mechanism of Action of Biguanide, Thiozolidinediones, Alpha-Glucosidase Inhibitors
- Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
- Figure 9: Mechanism of Action of Thiozolidinediones
- Figure 10: Mechanism of Action of DPP IV Inhibitors
- Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010
- Figure 12: Canagliflozin, Type 2 Diabetes, Global, Sales Forecasts (\$m), 2013–2020
- Figure 13: Canagliflozin, Type 2 Diabetes, The US, Sales Forecasts (\$m), 2013–2020
- Figure 14: Canagliflozin, Type 2 Diabetes, The UK, Sales Forecasts (\$m), 2013–2020
- Figure 15: Canagliflozin, Type 2 Diabetes, France, Sales Forecasts (\$m), 2013–2020
- Figure 16: Canagliflozin, Type 2 Diabetes, Germany, Sales Forecasts (\$m), 2013–2020
- Figure 17: Canagliflozin, Type 2 Diabetes, Italy, Sales Forecasts (\$m), 2013–2020
- Figure 18: Canagliflozin, Type 2 Diabetes, Spain, Sales Forecasts (\$m), 2013–2020
- Figure 19: Canagliflozin, Type 2 Diabetes, Japan, Sales Forecasts (\$m), 2016–2020
- Figure 20: Canagliflozin, Type 2 Diabetes, Sales Distribution by Country (%), 2020
- Figure 21: Patients Approved for the Drug

Ordering: Order Online - <http://www.researchandmarkets.com/reports/2075326/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.



Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: Canagliflozin (Type 2 Diabetes) - Analysis and Forecasts to 2020
Web Address: <http://www.researchandmarkets.com/reports/2075326/>
Office Code: OC8DIMPKMROOWU

Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic (PDF) - Single User:	<input type="checkbox"/>	EUR 1518
Electronic (PDF) - Site License:	<input type="checkbox"/>	EUR 3036
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/>	EUR 4554

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____ Last Name: _____

Email Address: * _____

Job Title: _____

Organisation: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
 - American Express
 - Diners Club
 - Master Card
 - Visa

Cardholder's Name _____

Cardholder's Signature _____

Expiry Date _____ | _____

Card Number _____

CVW Number _____

Issue Date _____ | _____

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World